EFFECT OF A ‘PROGESTIN ONLY’ CONTRACEPTIVE ON PLATELET AGGREGATION IN A PAKISTANI SET OF POPULATION
Abstract
Background: Safe use of progestin-only hormonal preparations has remained quite controversialthough they are being employed in various disorders very commonly. These hormones result in anumber of adverse effects in the body, the most drastic being predisposition to higher risk ofthromboembolism with reports of involvement of platelets. Despite a large number of studies, nodefinite inference had been derived regarding the effects of these agents on blood coagulation. Ithas been reported that the response in various ethnic groups may vary. Therefore this study isdesigned to observe the effects of progestin-only hormonal contraceptives regarding primaryhemostasis in our population. Methods: We carried out this study on 50 women divided into twoequal groups of 25 each, namely, a group of users of Progestin-only injectable hormonalcontraceptive Norethisterone oenanthate 200 mg used as a 2-monthly injection and a control groupand studied platelet aggregation against ADP, Collagen, Epinephrine and Ristocetin. Results:There was no statistical difference regarding the platelet aggregation studies against ADP,collagen, epinephrine and ristocetin between users and nonusers of progestin-only injectablecontraceptive. The menstrual irregularities were found to be more frequent in users of injectablehormonal contraceptives than in non-users, especially amenorrhea and irregularities of menstrualflow. In users of injectable hormonal contraceptives, hemoglobin and hematocrit were slightlybetter maintained as compared to non-users. Conclusion: This suggests that Norethisteroneoenanthate at currently used doses does not increase the platelet aggregation against ADP,collagen, epinephrine and ristocetin in our population.Key Words: Progestin, Norethisterone, Contraceptive, Coagulation, Thrombosis, Thrombophilia,Platelet Aggregation.References
Lobo RA, Stanczyk FZ. New knowledge in the physiology of
hormonal contraceptives. Am J Obstet Gynecol 1994;170(5
Pt 2): 1499-1507.
Loose-Mitchell DS, Stancel GM. Estrogens And Progestins.
In: Hardman JG, Limbird LE, Gilman AG, editors.Goodman
& Gilman’s Pharmacological Basis Of Therapy. 10th ed; New
York:McGraw Hill Companies,Inc;2001.p.1628;
Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB.
Sex steroids used in hormonal treatment increase vascular
procoagulant activity by inducing thrombin receptor (PAR-1)
expression: role of the glucocorticoid receptor. Circulation
;104(23): 2826-31.
Setiabudy RD, Affandi B, Witjaksono B, Wirawan R,
Hendratna M, Hidayat E. The effect of Norplant on some
hemostatic parameters in Indonesian women. Southeast
Asian J Trop Med Public Health. 1993; 24 Suppl 1:234-36.
Viegas OA, Singh K, Koh S, Singh P, Ratnam SS. The
effects of Norplant on clinical chemistry in Singaporean
acceptors after 1 year of use: I. Haemostatic changes.
Contraception1988;38(3):313-23.
Howie PW, Mallinson AC, Prentice CR, Horne CH, McNicol
GP. Effect of combined oestrogen-progestogen oral
contraceptives, oestrogen, and progestogen on antiplasmin
and antithrombin activity. Lancet 1970; 2:1329-32.
Leck I, Thomson JM, Bocaz JA, Barja P, Bonnar J, Daly L,
et al. A multicentre study of coagulation and haemostatic
variables during oral contraception: variations with
geographical location and ethnicity. Task Force on Oral
Contraceptives – WHO Special Programme of Research,
Development and Research Training in Human
Reproduction. Int J Epidemiol 1991;20(4):913-20.
Ferreira AC, Montes MB, Franceschini SA, Toloi MR.
Third-generation progestogen type influences hemostatic
changes caused by oral contraceptives in Brazilian women.
Contraception 2001;64(6):353-56.
Gader A, Bahakim H, Awadalla S, Malaika S. Ethnic
variations in the haemostatic system: comparison between
Arabs, Westerners (Europeans and Americans), Asians and
Africans. Blood Coagul Fibrinolysis 1995;6(6):537-42.
Bocaz JA, Barja P, Bonnar J, Daly L, Carrol A, Coutinho E,
et al. Differences in coagulation and hemostatic parameters
in normal women of childbearing age from different ethnic
groups and geographical locations. Task Force on Oral
Contraceptives – WHO Special Programme of research,
Development and Research Training in Human
Reproduction. Thromb Haemost 1986;55(3):390-95.
Spitzer WO, Lewis MA, Heineman LA, Thorogood M,
MacRae KD. Third generation oral contraceptives and risk of
venous thromboembolic disorders: an international casecontrol study. Transnational Research Group on Oral
Contraceptives and health of Young Women. BMJ 1996;
:83-88.
Grady D, Wenger, NK, Herrington D, Khan S, Furberg C,
Hunninghake D, et al. Postmenopausal hormone therapy
increases the risk for venous thromboembolism. The Heart
and Estrogen/progestin Replacement Study (HERS). Ann.
Intern Med 2000;132:689-96.
Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P,
Marsh S. Risk of venous thromboembolism in users of
hormone replacement therapy. Lancet 1996;348:977-80.
Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk
of idiopathic cardiovascular death and non fatal venous
thromboembolism in women using oral contraceptives with
differing progestogen components. Lancet 1995;346:1589-
Jick, H, Derby LE, Myers MW, Vasilakis C, Newton KM.
Risk of hospital admission for idiopathic venous
thromboembolism among users of postmenopausal estrogens.
Lancet 1996;348: 981-83.
Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal
estrogen use, cigarette smoking and cardiovascular morbidity
in women over 50: the Framingham Study. N Engl J Med
;313:1038-43.
Scholz D, Carmichael JM. Contraception. In: Herfindal ET,
Gourley DR, editors. Textbook Of Therapeutics, Drugs and
Disease Management, 7th edition Philadelphia:Lippincott
Williams & Wikins 2000. p.2024;.
WHO Collaborative Study of Cardiovascular Disease and
Steroid Hormone Contraception. Venous thromboembolic
disease and combined oral contraceptives: results of
international case-control study. Lancet 1995; 346:1575-82.
WHO Collaborative Study of Cardiovascular Disease and
Steroid Hormone Contraception. Effect of different
progestogens in low estrogen oral contraceptives on venous
thromboembolic disease. Lancet. 1995; 346:1582-88.
Paros NL. Side-Effects of Oral Contraceptives. Br Med J.
; 5383:630-5.
Loehry CA. Pulmonary emboli in young adults. Br Med J
; 5499:1327-8.
Inman WHW, Vessey MP. Investigation of deaths from
pulmonary, coronary, and cerebral thrombosis and embolism
in women of childbearing age. BMJ 1968; 2(599):193-9.
Budev MM, Thacker HL. Contraceptive Preparations and the
Risk of VTE. The Cleveland Clinic 2003. Available
from:http://www.clevelandclinicmeded.com/diseasemanage
ment/women/exogenous/exogenous.htm#top
Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ,
Lipinska I, et al. Increased platelet aggregability associated
with platelet GPIIIa PlA2 polymorphism: the Framingham
Offspring Study. Arterioscler Thromb Vasc Biol 1999;
(4):1142-47.
O'Donnell CJ, Larson MG, Feng D, Sutherland PA,
Lindpaintner K, Myers RH, et al. Genetic and environmental
contributions to platelet aggregation: the Framingham heart
study. Circulation 2001; 103(25):3051-56.
Michelson AD, Furman MI, Goldschmidt-Clermont P,
Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa
J Ayub Med Coll Abbottabad 2005;17(3)
Pl(A) polymorphisms display different sensitivities to
agonists. Circulation 2000; 101(9):1013-8.
Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny
JL, Aiach M, et al. Adenosine diphosphate-induced platelet
aggregation is associated with P2Y12 gene sequence
variations in healthy subjects. Circulation 2003; 108(8):989-
Ciavatti M, Davenas E, Blache D, Monnier MA, Renaud S.
Biosynthesis of platelet lipids in relation to aggregation in
women using oral contraceptives. Contraception 1982;
(6):629-38.
Meng YX, Jiang HY, Chen AJ, Lu FY, Yang H, Zhang MY,
et al. Hemostatic changes in women using a monthly
injectable contraceptive for one year. Contraception 1990;
(4):455-66.
Task Force for Epidemiological Research on Reproductive
Health, UNDP/UNPF/WHO/WB Special Programme of
Research, Development and Research Training in Human
Reproduction, WHO. Effects of contraceptives on
hemoglobin and ferritin. Contraception 1998;58(5):262-73.
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
